A systematic review of genome-wide association studies of antipsychotic response

Josiah D. Allen, Jeffrey R Bishop

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Clinical symptom response to antipsychotic medications is highly variable. Genome-wide association studies (GWAS) provide a 'hypothesis-free' method of interrogating the genome for biomarkers of antipsychotic response. We performed a systematic review of GWAS findings for antipsychotic efficacy or effectiveness. 14 studies met our inclusion criteria, ten of which examined antipsychotic response using quantitative rating scales to measure symptom improvement. 15 genome-wide significant loci were identified, seven of which were replicated in other antipsychotic GWAS publications: CNTNAP5, GRID2, GRM7, 8q24 (KCNK9), PCDH7, SLC1A1 and TNIK. Notably, four replicated loci are involved in glutamatergic pathways. Additional validation and evaluation of the biological significance of these markers is warranted. These markers should also be evaluated for clinical utility, especially in the context of other validated pharmacogenomic variants (e.g., CYP450 genes). These findings may generate new avenues for development of novel antipsychotic treatments.

Original languageEnglish (US)
Pages (from-to)291-306
Number of pages16
Issue number4
StatePublished - Mar 2019

Bibliographical note

Publisher Copyright:
© 2019 Future Medicine Ltd.


  • GWAS
  • antipsychotic
  • genome-wide association study
  • pharmacogenomics
  • psychopharmacology
  • schizophrenia
  • systematic review
  • treatment response

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural


Dive into the research topics of 'A systematic review of genome-wide association studies of antipsychotic response'. Together they form a unique fingerprint.

Cite this